Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

2519.308 - 2546.655 Dr. Andrea Apolo

Yeah, and I'm glad that it was randomized because, you know, someone can argue, well, they received a systemic treatment with a checkpoint. But they did have a monotherapy checkpoint arm, and the pathologic response rate was much lower. That's right. Sorry, I could have said that, but it was 23%, so half. So it's nice to see that putting the TAR200 in the bladder intensified that.